Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naloxone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 8/20 | 0.74 |
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.74 |
| ▸ | OPRD1 known ✓ | P41143 | 6/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.74 |
| ▸ | CYBB | P04839 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naltrexone SCHEMBL9837116 | 0.95 | OPRK1 (0.68) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naloxone SCHEMBL2588324 | 0.95 | OPRK1 (0.71) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naloxone SCHEMBL28209122 | 0.95 | OPRK1 (0.71) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Nalmefene SCHEMBL7574800 | 0.93 | OPRK1 (0.64) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naloxone SCHEMBL4950697 | 0.93 | OPRK1 (0.68) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Nalorphine SCHEMBL19816078 | 0.91 | OPRK1 (0.63) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naloxone SCHEMBL5657970 | 0.91 | OPRM1 (0.66) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Nalmefene SCHEMBL3414261 | 0.88 | OPRK1 (0.69) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naltrexone SCHEMBL2425204 | 0.86 | OPRM1 (0.71) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| Naloxone SCHEMBL24542257 | 0.86 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6CYBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1514729-B | Sustained-release analgesic compounds | CONTROL DELIVERY SYS INC | 2012-09-05 | — | — | CN | disclosed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| EP-2032579-A2 | PROCESS USEFUL IN THE PREPARATION OF MORPHINAN ANTAGONISTS | Alpharma (Bermuda) Investments Ltd (BM) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009004491-A2 | PREPARATION OF OXYCODONE | ALPHARMA (BERMUDA) INVESTMENTS LTD. (DK) | 2009-01-08 | — | — | WO | disclosed |
| WO-2007137785-A2 | PROCESS USEFUL IN THE PREPARATION OF MORPHINAN ANTAGONISTS | ALPHARMA (BERMUDA) INVESTMENTS LTD (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20030099960-A1 | Administration of epirubicin for use in the treatment of cancer; obtain sample, incubate with antitumor agent, monitor adjustment in glucoronyltransferase activity, evaluate effectiveness antitumor agent | THE UNIVERSITY OF CHICAGO | 2003-05-29 | — | — | US | disclosed |